Literature DB >> 3290383

Passive acquired mucosal immunity to group A streptococci by secretory immunoglobulin A.

D Bessen1, V A Fischetti.   

Abstract

We present a model in which animals are passively immunized at a mucosal site, allowing one to evaluate immunological protection at the mucosal level only. Affinity-purified, anti-M protein sIgA administered intranasally protected mice against systemic infection after intranasal challenge with group A streptococci. In contrast, anti-M protein serum Ig administered intranasally was not protective at this site, although it neutralized the antiphagocytic property of M protein and promoted phagocytosis. Protection by sIgA occurred despite the lower immunoreactivity of sIgA to purified M protein compared with serum Ig. The data suggest that sIgA can protect at the mucosa and may preclude the need for opsonic IgG in preventing streptococcal infection.

Entities:  

Mesh：

Substances：

Year:  1988        PMID： 3290383      PMCID： PMC2189674          DOI： 10.1084/jem.167.6.1945

Source DB:  PubMed          Journal:  J Exp Med        ISSN： 0022-1007            Impact factor:   14.307


  17 in total

Review 1.  M proteins of group A streptococci.

Authors:  E N Fox
Journal:  Bacteriol Rev       Date:  1974-03

2.  Protection against enteric bacterial infection by secretory IgA antibodies.

Authors:  E S Fubara; R Freter
Journal:  J Immunol       Date:  1973-08       Impact factor: 5.422

3.  Requirements for the opsonic activity of human IgG directed to type 6 group A streptococci: net basic charge and intact Fc region.

Authors:  V A Fischetti
Journal:  J Immunol       Date:  1983-02       Impact factor: 5.422

4.  Induction of local immunity to group A streptococci type M50 in mice by non-type-specific mechanisms.

Authors:  D N Kurl; A Stjernquist-Desatnik; C Schalén; P Christensen
Journal:  Acta Pathol Microbiol Immunol Scand B       Date:  1985-12

5.  Restricted deposition of C3 on M+ group A streptococci: correlation with resistance to phagocytosis.

Authors:  J Jacks-Weis; Y Kim; P P Cleary
Journal:  J Immunol       Date:  1982-04       Impact factor: 5.422

6.  Protective study with a group A streptococcal M protein vaccine. Infectivity challenge of human volunteers.

Authors:  E N Fox; R H Waldman; M K Wittner; A A Mauceri; A Dorfman
Journal:  J Clin Invest       Date:  1973-08       Impact factor: 14.808

7.  The importance of the location of antibody binding on the M6 protein for opsonization and phagocytosis of group A M6 streptococci.

Authors:  K F Jones; V A Fischetti
Journal:  J Exp Med       Date:  1988-03-01       Impact factor: 14.307

8.  Location of variable and conserved epitopes among the multiple serotypes of streptococcal M protein.

Authors:  K F Jones; B N Manjula; K H Johnston; S K Hollingshead; J R Scott; V A Fischetti
Journal:  J Exp Med       Date:  1985-03-01       Impact factor: 14.307

9.  Persistence of type-specific antibodies in man following infection with group A streptococci.

Authors:  R C LANCEFIELD
Journal:  J Exp Med       Date:  1959-08-01       Impact factor: 14.307

10.  Streptococcal M6 protein expressed in Escherichia coli. Localization, purification, and comparison with streptococcal-derived M protein.

Authors:  V A Fischetti; K F Jones; B N Manjula; J R Scott
Journal:  J Exp Med       Date:  1984-04-01       Impact factor: 14.307
View more
  37 in total

Review 1.  Diversity of antibody-mediated immunity at the mucosal barrier.

Authors:  J P Bouvet; V A Fischetti
Journal:  Infect Immun       Date:  1999-06       Impact factor: 3.441

2.  Group A Streptococcus Infection of the Nasopharynx Requires Proinflammatory Signaling through the Interleukin-1 Receptor.

Authors:  Doris L LaRock; Raedeen Russell; Anders F Johnson; Shyra Wilde; Christopher N LaRock
Journal:  Infect Immun       Date:  2020-09-18       Impact factor: 3.441

3.  Host Pathways of Hemostasis that Regulate Group A Streptococcus pyogenes Pathogenicity.

Authors:  Victoria A Ploplis; Francis J Castellino
Journal:  Curr Drug Targets       Date:  2020       Impact factor: 3.465

Review 4.  Tissue tropisms in group A streptococcal infections.

Authors:  Debra E Bessen; Sergio Lizano
Journal:  Future Microbiol       Date:  2010-04       Impact factor: 3.165

Review 5.  Advances in potential M-protein peptide-based vaccines for preventing rheumatic fever and rheumatic heart disease.

Authors:  Michael R Batzloff; Manisha Pandey; Colleen Olive; Michael F Good
Journal:  Immunol Res       Date:  2006       Impact factor: 2.829

6.  Active and passive intranasal immunizations with streptococcal surface protein C5a peptidase prevent infection of murine nasal mucosa-associated lymphoid tissue, a functional homologue of human tonsils.

Authors:  Hae-Sun Park; P Patrick Cleary
Journal:  Infect Immun       Date:  2005-12       Impact factor: 3.441

7.  Antibody responses to Toxoplasma gondii in sera, intestinal secretions, and milk from orally infected mice and characterization of target antigens.

Authors:  T Chardès; I Bourguin; M N Mevelec; J F Dubremetz; D Bout
Journal:  Infect Immun       Date:  1990-05       Impact factor: 3.441

8.  A Quorum Sensing-Regulated Protein Binds Cell Wall Components and Enhances Lysozyme Resistance in Streptococcus pyogenes.

Authors:  Artemis Gogos; Juan Cristobal Jimenez; Jennifer C Chang; Reid V Wilkening; Michael J Federle
Journal:  J Bacteriol       Date:  2018-05-09       Impact factor: 3.490

9.  Clearance of Pseudomonas aeruginosa from the murine gastrointestinal tract is effectively mediated by O-antigen-specific circulating antibodies.

Authors:  G B Pier; G Meluleni; J B Goldberg
Journal:  Infect Immun       Date:  1995-08       Impact factor: 3.441

10.  Secretory immune responses in mouse vaginal fluid after pelvic, parenteral or vaginal immunization.

Authors:  M A Thapar; E L Parr; M B Parr
Journal:  Immunology       Date:  1990-05       Impact factor: 7.397
View more

北京卡尤迪生物科技股份有限公司 © 2022-2023.